As chronic lifestyle diseases surge and regulatory authorities like the US FDA, EMA, and NMPA demand stringent batch homogeneity, global pharmaceutical brands are divesting from fragmented sourcing in favor of vertically integrated CRO & CDMO alliances.
Traditional botanical medicines historically suffered from inconsistent secondary metabolite profiles. International pharmacopoeias now enforce chromatographic fingerprinting (HPLC, HPTLC, GC-MS), requiring multi-marker assay precision, limits on heavy metals, and zero pesticide residues.
Global supply chain disruptions have underscored the perils of relying on broker networks. Modern tier-1 pharmaceutical procurers require seed-to-patient traceability, validated pilot extraction pathways, and documented solvent recycling standards before entering multi-year contracts.
Classic Traditional Chinese Medicine formulations are undergoing massive pharmacological deconstruction. Phytochemical isolates and synergized fractions are being developed through randomized Phase I–IV clinical designs for mainstream metabolic, cardiovascular, and oncology supportive indications.
By merging laboratory-scale extraction optimization directly with in-house pilot reactors, technology transfer lead times decrease from 14 months to under 8 months.
Continuous chromatographic assaying ensures active compound variance remains within <1.5% across commercial multi-metric ton shipments, satisfying international drug master files (DMF).
MedGence (Yineng Pharma), headquartered in Changsha, Hunan, synthesizes 14+ years of botanical chemistry with advanced high-volume manufacturing throughput, creating structural cost and quality advantages.
Located adjacent to core Chinese botanical production regions, our sourcing infrastructure evaluates soil matrices, regional altitudes, and harvest timing across all 4 seasons to extract maximum biomolecule densities while maintaining GAP (Good Agricultural Practice) fidelity.
From micro-gram exploratory screening to 100,000-liter multi-effect countercurrent extraction tanks, our facilities eliminate pilot scaling hurdles. We preserve active ingredient stability through low-temperature vacuum concentration and spray-freeze drying.
We strictly isolate contract research accounts. Proprietary customer formulations, chromatography protocols, and custom fractional extraction sequences are protected via air-gapped data storage and legally enforced bilateral non-disclosure pacts.
Whether executing targeted preclinical pharmacology or turnkey contract manufacturing of finished dosage forms, our laboratory and pilot infrastructure supports every tier of product realization.
Deconvoluting plant matrices to discover novel bioactive alkaloids, saponins, flavonoids, and immunomodulatory polysaccharides utilizing liquid chromatography-mass spectrometry (LC-MS).
Explore Screening Protocol →Establishing precision HPTLC fingerprinting, quantitative HPLC assays, and GC residual testing parameters to establish verifiable, reproducible enterprise QA/QC monographs.
Review Analytical Services →Executing target validation via cell line screening, membrane receptor binding, LD50 acute toxicity, chronic organ toxicity models, and genetic mutagenicity evaluation.
Examine Preclinical Capabilities →Managing double-blind, placebo-controlled human clinical trials for dietary supplements and botanically derived New Drug Applications (NDA), backed by institutional hospital boards.
Discover Clinical Studies →Turnkey delivery across finished oral delivery vectors: softgels, enteric-coated tablets, hard capsules, effervescent granules, functional oral liquids, and standardized concentrated extracts.
Explore Formulation Types →Our validated chemical standards and contract manufacturing lines support 100+ distinguished medical enterprises and state key clinical research hospitals.
Key technical, compliance, and logistical clarifications for pharmaceutical supply managers and R&D directors.